載入中
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
一般交易時段
US$22.10
−US$0.61 · -2.69%
盤中時間採用ET。市場資料可能有所延遲。
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
日內區間
目前US$22.10
52週區間
目前US$22.10
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 6348.9萬 USD | 4136.4萬 USD | 3696.6萬 USD | 2565.4萬 USD | 1097.7萬 USD |
| 銷售、一般及管理費用 | 2054.7萬 USD | 1665.1萬 USD | 768.2萬 USD | 717.6萬 USD | 463.3萬 USD |
| 營業費用 | 8403.6萬 USD | 5801.5萬 USD | 4464.8萬 USD | 3283萬 USD | 1561萬 USD |
| 利息收入 | 1129.7萬 USD | 426.1萬 USD | 58.1萬 USD | 14.9萬 USD | — |
| 利息支出 | 6.3萬 USD | 10.7萬 USD | 15.2萬 USD | 14.4萬 USD | 22.4萬 USD |
| 折舊和攤銷 | 137.5萬 USD | 164.5萬 USD | 147.8萬 USD | 100.6萬 USD | 36.4萬 USD |
| 營業利益 | −8403.6萬 USD | −5801.5萬 USD | −4464.8萬 USD | −3283萬 USD | −1561萬 USD |
| 淨利 | −7415.1萬 USD | −5798.2萬 USD | −4282.3萬 USD | −3218萬 USD | −892.7萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$78.67
上漲空間 255.97%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年6月21日 | 1:12 | — | — |
已生效 2024年6月21日
1:12
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM622.69萬0.01%785.63億 USD0.19%US$275.93-0.64%
Vanguard Russell 2000 ETFVTWO176.52萬0.01%180億 USD0.06%US$111.44-0.69%
iShares Biotechnology ETFIBB161.95萬0.02%104.01億 USD0.44%US$197.93-2.66%
iShares Micro-Cap ETFIWC77.17萬0.06%13.33億 USD0.60%US$181.73-0.89%
Vanguard Health Care ETFVHT77.07萬0.00%220億 USD0.09%US$309.71-1.78%
ALPS Medical Breakthroughs ETFSBIO56.35萬0.30%1.88億 USD0.50%US$52.89-2.29%
Avantis U.S. Small Cap Equity ETFAVSC49.16萬0.02%30.38億 USD0.25%US$69.57-0.09%
iShares Russell 2000 Growth ETFIWO44.77萬0.00%142.49億 USD0.24%US$352.01-0.95%iShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTALPS Medical Breakthroughs ETFSBIOAvantis U.S. Small Cap Equity ETFAVSCiShares Russell 2000 Growth ETFIWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
